Characterisation of luminal and triple-negative breast cancer with HER2 Low protein expression-Reference-Cited by-同舟云学术

Characterisation of luminal and triple-negative breast cancer with HER2 Low protein expression

Published:2023-12 Issue: Volume:195 Page:113371
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Atallah Nehal M.,Haque Maria^ORCID,Quinn Cecily,Toss Michael S.,Makhlouf Shorouk^ORCID,Ibrahim Asmaa^ORCID,Green Andrew R.,Alsaleem Mansour,Rutland Catrin S.,Allegrucci Cinzia^ORCID,Mongan Nigel P.,Rakha Emad

Funder

Ministry of Higher Education and Scientific Research

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference81 articles.

1. HER2 directed antibody-drug-conjugates beyond T-DM1 in breast cancer;Rinnerthaler;Int J Mol Sci,2019

2. HER2-low breast cancer: pathological and clinical landscape;Tarantino;J Clin Oncol,2020

3. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study;Banerji;Lancet Oncol,2019

4. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer;Modi;N Eng J Med,2022

5. Marchiò C, Annaratone L, Marques A, Casorzo L, Berrino E, Sapino A, editors. Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond. Seminars in cancer biology; 2021. Elsevier.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular and Clinical Portrait of HER2-low Invasive Lobular Carcinomas;Modern Pathology;2024-05

2. Breast cancer highlights from 2023: Knowledge to guide practice and future research;The Breast;2024-04

3. In silico evaluation of potential breast cancer receptor antagonists from GC-MS and HPLC identified compounds in Pleurotus ostreatus extracts;RSC Advances;2024

4. Possibility of Human Epidermal Growth Factor Receptor 2 Expression as a Treatment Selection Indicator in Early Triple-Negative Breast Cancer;2024